Income statement
USD
Annual
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -1K | -12K | -16K | -20K | -26K |
| Operating Income | -494K | -2M | -940K | -1M | -27M |
| EBITDA | -493K | -2M | -924K | -1M | -24M |
| Net Income | -387K | -2M | -2M | -2M | -24M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.003
+0.00% today
1Y Change
+2900.00%
Window
Jun 23, 2025 → Jun 12, 2026
Coverage: 240 bars · Jun 23, 2025 → Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
THC Therapeutics, Inc. (THCT) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and up 2900.0% across the available one-year price window (Jun 23, 2025 → Jun 12, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +74.2%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +74.2%, free cash flow +79.6% with operating margin 0.0% and ROIC 20.4%. Stock Foundry combines THCT price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
THCT
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
THCT Max Drawdown
-99.47%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for THCT and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$23.6M
-1126.4% YoY
Free Cash Flow
-$331.0K
+43.7% YoY
Revenue Growth
+0.0%
EPS Growth
+74.2%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -1K | -12K | -16K | -20K | -26K |
| Operating Income | -494K | -2M | -940K | -1M | -27M |
| EBITDA | -493K | -2M | -924K | -1M | -24M |
| Net Income | -387K | -2M | -2M | -2M | -24M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Cash & Equivalents | 10 | 32 | 296K | 43K | 318K |
| Total Assets | 13K | 207K | 480K | 85K | 520K |
| Total Liabilities | 3M | 3M | 3M | 2M | 1M |
| Shareholder Equity | -3M | -3M | -2M | -2M | -749K |
| Total Debt | 791K | 801K | 761K | 430K | 178K |
| Net Debt | 791K | 801K | 465K | 387K | -140K |
Cash flow positioning
Latest Full Year
Operating Cash Flow
330K
+43.9% YoY
Capital Expenditures
1K
Free Cash Flow
331K
+43.7% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
12.1%
Debt / Equity
-0.24x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.